Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
5.37
+0.27 (5.34%)
At close: Jul 8, 2026, 4:00 PM EDT
5.45
+0.08 (1.45%)
After-hours: Jul 8, 2026, 7:08 PM EDT
Immuneering Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
55
Market Cap
357.78M
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 316.95K | -1.76M | -84.76% |
| Dec 31, 2021 | 2.08M | -231.57K | -10.02% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| OmniAb | 28.94M |
| Foghorn Therapeutics | 28.22M |
| Zentalis Pharmaceuticals | 26.87M |
| Lineage Cell Therapeutics | 14.78M |
| Opus Genetics | 11.98M |
| Fate Therapeutics | 6.32M |
| InflaRx | 33.82K |
| Inhibikase Therapeutics | 1.00 |
IMRX News
- 18 hours ago - Immuneering initiated with an Overweight at Cantor Fitzgerald - TheFly
- 23 days ago - Immuneering appoints Andrew Gengos as CFO - TheFly
- 23 days ago - Immuneering Appoints Andrew Gengos as Chief Financial Officer - GlobeNewsWire
- 27 days ago - Immuneering Transcript: AGM 2026 - Transcripts
- 27 days ago - Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer - GlobeNewsWire
- 5 weeks ago - Immuneering announces updated clinical data from atebimetinib combination trial - TheFly
- 5 weeks ago - Immuneering Transcript: Study result - Transcripts
- 5 weeks ago - Immuneering Press release: Study result - Filings